• In January 2026, PTC Therapeutics issued full-year 2026 guidance, projecting total product revenue of US$700 million to US$800 million, excluding Evrysdi royalty and collaboration revenue, while also reporting stronger-than-expected preliminary 2025 product and royalty results driven by Sephience.
• The company coupled its outlook with updates on regulatory and pipeline progress, including FDA alignment on a Phase 3 Huntington’s trial for votoplam and continued engagement on vatiquinone and Translarna, signaling how future growth may depend on both launch execution and clinical milestones.
• We will now examine how PTC’s new 2026 product revenue outlook, alongside Sephience launch momentum, may reshape its investment narrative.

Find companies with promising cash flow potential yet trading below their fair value.

PTC Therapeutics Investment Narrative Recap

To own PTC Therapeutics, you need to believe that Sephience can anchor a broader rare disease franchise while pipeline assets gradually diversify revenue away from Translarna and Emflaza. The new 2026 product revenue guidance of US$700 million to US$800 million reinforces Sephience’s early traction, but does not materially change the near term focus on launch execution and the key risk around concentration in a few products.

The most relevant update here is the stronger than expected preliminary 2025 product and royalty performance, driven by Sephience. That context makes the 2026 outlook easier to frame, because it suggests the guidance is being set after an early read on Sephience uptake and while PTC is still investing heavily in R&D and SG&A to support future catalysts such as the planned Phase 3 Huntington’s trial for votoplam.

Yet alongside this constructive setup, investors should be aware that...

PTC Therapeutics' narrative projects $1.3 billion revenue and $55.4 million earnings by 2028.

Uncover how PTC Therapeutics' forecasts yield a $81.86 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community range from about US$81.86 to US$213.28, with some members seeing very large upside. Against that optimism, PTC’s reliance on Sephience and a small set of products leaves its revenue heavily exposed to any future regulatory or market access shocks, so it is worth comparing several of these viewpoints before forming a view.

Explore 3 other fair value estimates on PTC Therapeutics - why the stock might be worth just $81.86!

Build Your Own PTC Therapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your PTC Therapeutics research is our analysis highlighting 3 key rewards and 5 important warning signs that could impact your investment decision.
• Our free PTC Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PTC Therapeutics' overall financial health at a glance.

No Opportunity In PTC Therapeutics?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.